Publications & Presentations
Publications & Presentations
BVD Authored
AACR ANNUAL MEETING, 2023
Combining ulixertinib (ERK1/2 inhibitor) with EGFR and BRAF inhibition yields significant efficacy in preclinical BRAFV600E mutant colorectal cancer models
AACR Annual Meeting, 2023
The combination of ulixertinib (ERK1/2 inhibitor) and KRASG12C inhibition demonstrates significant efficacy in preclinical models
Neuro-Oncology, March 2023 (print); July 2022 (online)
The first-in-class ERK inhibitor ulixertinib shows promising activity in mitogen-activated protein kinase (MAPK)-driven pediatric low-grade glioma models
Melanoma Research, August 2022 (print); May 2022 (online)
Case report: response to the ERK1/2 inhibitor ulixertinib in BRAF D594G cutaneous melanoma
AACR Annual Meeting, April 2022
ERK1/2 inhibitor ulixertinib demonstrates activity in atypical (non-V600) BRAF mutant models
AACR ANNUAL MEETING, APRIL 2022
Significant efficacy demonstrated with the combination of ulixertinib (ERK1/2 inhibitor) and CDK4/6 inhibitors in MAPK altered models
AACR ANNUAL MEETING, APRIL 2022
The characterization of in vitro models demonstrating a significant delay of acquired resistance to ulixertinib (ERK1/2)
AACR ANNUAL MEETING, APRIL 2022
Identification of combination partners to combat acquired resistance to ulixertinib (ERK1/2 inhibitor) using transcriptomics
Investigational New Drugs, June 2021 (print); January 2021 (online)
Characterization and management of ERK inhibitor associated dermatologic adverse events: analysis from a nonrandomized trial of ulixertinib for advanced cancers
Cancer Discovery, September 2018 (print); June 2018 (online)
Real-time genomic characterization of advanced pancreatic cancer to enable precision medicine
Cancer Chemotherapy and Pharmacology, June 2018 (print), March 2018 (online)
Effect of ulixertinib, a novel ERK1/2 inhibitor, on the QT/QTc interval in patients with advanced solid tumor malignancies
Cancer Discovery, February 2018 (print); December 2017 (online)
First-in-class ERK1/2 inhibitor ulixertinib (BVD-523) in patients with MAPK mutant advanced solid tumors: results of a Phase I dose-escalation and expansion study
Joint Meeting of the 9th World Congress of Melanoma and 14th International Congress of the Society for Melanoma Research, October 18 – 21, 2017
Activity of the ERK1/2 inhibitor ulixertinib in patients with BRAF and NRAS mutant melanoma
Molecular Cancer Therapeutics, November 2017 (print); September 2017 (online)
Targeting the MAPK signaling pathway in cancer: promising preclinical activity with the novel selective ERK1/2 inhibitor BVD-523 (ulixertinib)
American Society of Clinical Oncology (ASCO), June 2017
A first-in-class Phase 1 dose-escalation study of the novel oral ERK1/2 kinase inhibitor BVD-523 (ulixertinib) in patients with advanced solid tumors
American Association for Cancer Research (AACR), April 2017
Activity of ERK1/2 inhibitor ulixertinib (BVD-523) in patients with BRAF and NRAS mutant melanoma
American Society of Clinical Oncology (ASCO), June 2015
Dose escalation stage of a first-in-class Phase 1 study of the novel oral ERK1/2 kinase inhibitor BVD-523 (ulixertinib) in patients with advanced solid tumors
American Association for Cancer Research (AACR), April 2015
The selective ERK inhibitor BVD-523 is active in models of MAPK pathway-dependent cancers, including those with intrinsic and acquired drug resistance
PLoS One, Aug 2014
Systematic repurposing screening in xenograft models identifies approved drugs with novel anti-cancer activity
Supporting Literature
Biochemical Journal, April 2023
ERK1/2 inhibitors act as monovalent degraders inducing ubiquitylation and proteasome-dependent turnover of ERK2, but not ERK1
Cancers, 2022
ERK Inhibitor Ulixertinib Inhibits High-Risk Neuroblastoma Growth In Vitro and In Vivo